Skip to content
Wednesday 2 September 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,756.45
-0.30%
DAX
25,843.34
-0.49%
CAC 40
8,280.63
-0.26%
STOXX 50
6,363.17
-0.09%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Wednesday 10 February 2021 8:17 pm  |  Updated:  Saturday 13 February 2021 11:03 am

Hospital in Israel says it may have found Covid-19 cure as all treated patients make full recovery

By: Michiel Willems

Add as a preferred source on Google

A number of severely ill Covid-19 patients made a full recovery within five days after being treated with a relatively unknown cancer drug, according to multiple media reports in Israel today.

Researchers at the Ichilov Hospital in Tel Aviv told Israeli’s KAN News network that out of 30 seriously ill Covid-patients that were treated with the drug, 29 showed a significant improvement within two days and all were released within three to five days.

One patient ultimately did recover but this took “a few days” longer, according to the hospital’s Covid-19 lead, professor Nadir Arber.

Cancer drug

The medication, called EXO-CD24, is a targeted drug that was reportedly developed as a cure for certain types of cancer.

Ichilov hospital decided to administer the drug to 30 moderate-to-seriously ill Covid-19 patients, which led to a success rate of 96% within a set trial period of five days, explained Arber, who is part of the hospital’s Integrated Cancer Prevention Centre.

EXO-CD24 is relatively inexpensive and must be given once a day for a period of five days. It fights the cytokine storm, a potentially lethal immune overreaction as a result of a coronavirus infection, which is believed to be responsible for many Covid-related deaths.

The drug uses so-called ‘exosomes’ – tiny carrier pouches that shuttle materials between cells – to deliver a protein called CD24 to the lungs, which Arber has been studying for decades.

“This protein is located on the surface of cells and has a well-known and important role in regulating the immune system,” researcher Shiran Shapira, who is part of Arber’s research team, told the Times of Israel earlier today.

Israeli media hail the results as “a huge breakthrough” and the hospital has reportedly reached out to the country’s Ministry of Health, requesting them for permission to extend and expand the trial.

האם נמצאה תרופה לקורונה? @kettydor חושפת את התרופה החדשנית והניסיונית באיכילוב שריפאה 96% מהחולים#חדשותהערב pic.twitter.com/YBUuHIIf7V

— כאן חדשות (@kann_news) February 4, 2021

KAN News first reported the findings.

Read more

NHS data counters claims that £330m Palantir deal has led to ‘no improvement’

Brit are seeking financial support from the ‘Bank of Mum and Dad’ to afford private healthcare.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus
  • International

Trending Articles

  • Vodafone and Deliveroo look to patch up Reform ties after Yusuf prison threats

  • Trio of firms poised to quit London Stock Exchange as exodus gathers pace

  • Jaguar reveals the Type 01’s screen-free interior

  • Easyjet’s over-60s recruitment push is economically necessary

  • Jim O’Neill: Capital gains tax hike ‘looms’ as top option for Burnham

More from Morning Wire

  • NHS data counters claims that £330m Palantir deal has led to ‘no improvement’

    Tech
    Brit are seeking financial support from the ‘Bank of Mum and Dad’ to afford private healthcare.
  • Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization

    Business Wire
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

    Business Wire
  • New Drill-Free Treatment Helps Patients to Feel at Ease in the Dentist Chair

    Business Wire
  • Limbic Becomes First AI-Led Mental Healthcare Company Selected for FDA TEMPO

    Business Wire
  • Barts North Wing would be a worthy Toast Award winner

    Toast the City
    Ornate St. Bartholomews Hospital mural, depicting biblical scenes, on a grand staircase with carved wood and gold trim
  • Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook